Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 735   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
     

    Article Cited by others

REVIEW ARTICLE

Intellectual property rights: An overview and implications in pharmaceutical industry

Saha Chandra Nath, Bhattacharya Sanjib

Year : 2011| Volume: 2| Issue : 2 | Page no: 88-93

   This article has been cited by
 
1 Assessment of knowledge, attitude and practice regarding intellectual property rights among dental task force attending private dental colleges in Navi Mumbai: a cross-sectional study
Vaibhav Kumar,Venetia Aranha,Nikhil Bhanushali,Romi Jain,Swarali Atre,Shishir Singh
Journal of Medicine and Life. 2021; 14(1): 93
[Pubmed]  [Google Scholar] [DOI]
2 Waiver of Intellectual Property Rights on COVID-19 vaccine roll out
Katherine Pia M Cabatbat
Journal of Public Health. 2021;
[Pubmed]  [Google Scholar] [DOI]
3 Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages
Jabson Herber Profiro de Oliveira,Igor Eduardo Silva Arruda,José Izak Ribeiro de Araújo,Luise Lopes Chaves,Mônica Felts de La Rocca Soares,José Lamartine Soares-Sobrinho
Expert Opinion on Therapeutic Patents. 2021;
[Pubmed]  [Google Scholar] [DOI]
4 The role of intellectual property rights and package safety features in the prevention of counterfeit medicines
Katerina Ancevska-Netkovska,Katerina Brezovska,Nikola Geškovski,Jasmina Tonik-Ribarska,Biljana Petrovska-Jakimovska,Blagoj Achevski,Katerina Goracinova
Arhiv za farmaciju. 2020; 70(6): 332
[Pubmed]  [Google Scholar] [DOI]
5 Data Object Exchange (DOEx) as a Method to Facilitate Intraorganizational Collaboration by Managed Data Sharing: Viewpoint
Ronald G Hauser,Ankur Bhargava,Ronald Talmage,Mihaela Aslan,John Concato
JMIR Medical Informatics. 2020; 8(10): e19267
[Pubmed]  [Google Scholar] [DOI]
6 An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Evelien Moorkens,Arnold G. Vulto,Isabelle Huys
mAbs. 2020; 12(1): 1743517
[Pubmed]  [Google Scholar] [DOI]
7 Partnership Efforts – Their Potential to Reduce the Challenges that Confront Regulators and Pharmaceutical Industry
Sandeep Kumar Dhiman,Vikram Gummadi,Harish Dureja
Applied Clinical Research, Clinical Trials and Regulatory Affairs. 2019; 6(1): 7
[Pubmed]  [Google Scholar] [DOI]
8 Trans-Pacific Partnership Agreement and Its Impact on Accessibility and Affordability of Medicines
Yan Yee Yap,Che Pui Wong,Kah Seng Lee,Long Chiau Ming,Tahir Mehmood Khan
Therapeutic Innovation & Regulatory Science. 2017; 51(4): 446
[Pubmed]  [Google Scholar] [DOI]
9 Fostering innovative product development for neglected tropical diseases through partnerships
Amy Starr,Katy M Graef,Jennifer Dent
Pharmaceutical Patent Analyst. 2016; 5(6): 391
[Pubmed]  [Google Scholar] [DOI]
10 Polypharmacology Shakes Hands with Complex Aetiopathology
James S. Brodie,Vincenzo Di Marzo,Geoffrey W. Guy
Trends in Pharmacological Sciences. 2015; 36(12): 802
[Pubmed]  [Google Scholar] [DOI]

 

Read this article